178 related articles for article (PubMed ID: 23907406)
1. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Falchook GS; Fu S; Naing A; Hong DS; Hu W; Moulder S; Wheler JJ; Sood AK; Bustinza-Linares E; Parkhurst KL; Kurzrock R
Invest New Drugs; 2013 Oct; 31(5):1192-200. PubMed ID: 23907406
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S; Hu W; Iyer R; Kavanagh JJ; Coleman RL; Levenback CF; Sood AK; Wolf JK; Gershenson DM; Markman M; Hennessy BT; Kurzrock R; Bast RC
Cancer; 2011 Apr; 117(8):1661-9. PubMed ID: 21472713
[TBL] [Abstract][Full Text] [Related]
3. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Braiteh F; Soriano AO; Garcia-Manero G; Hong D; Johnson MM; Silva Lde P; Yang H; Alexander S; Wolff J; Kurzrock R
Clin Cancer Res; 2008 Oct; 14(19):6296-301. PubMed ID: 18829512
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
Fang F; Balch C; Schilder J; Breen T; Zhang S; Shen C; Li L; Kulesavage C; Snyder AJ; Nephew KP; Matei DE
Cancer; 2010 Sep; 116(17):4043-53. PubMed ID: 20564122
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Chu BF; Karpenko MJ; Liu Z; Aimiuwu J; Villalona-Calero MA; Chan KK; Grever MR; Otterson GA
Cancer Chemother Pharmacol; 2013 Jan; 71(1):115-21. PubMed ID: 23053268
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Gaillard SL; Zahurak M; Sharma A; Durham JN; Reiss KA; Sartorius-Mergenthaler S; Downs M; Anders NM; Ahuja N; Rudek MA; Azad N
Cancer; 2019 Aug; 125(16):2837-2845. PubMed ID: 31012962
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Wheler JJ; Janku F; Falchook GS; Jackson TL; Fu S; Naing A; Tsimberidou AM; Moulder SL; Hong DS; Yang H; Piha-Paul SA; Atkins JT; Garcia-Manero G; Kurzrock R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):495-501. PubMed ID: 24435060
[TBL] [Abstract][Full Text] [Related]
10. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Wong-Brown MW; van der Westhuizen A; Bowden NA
BMC Cancer; 2022 Jan; 22(1):100. PubMed ID: 35073851
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Pauer LR; Olivares J; Cunningham C; Williams A; Grove W; Kraker A; Olson S; Nemunaitis J
Cancer Invest; 2004; 22(6):886-96. PubMed ID: 15641487
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
13. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
Lassen U; Molife LR; Sorensen M; Engelholm SA; Vidal L; Sinha R; Penson RT; Buhl-Jensen P; Crowley E; Tjornelund J; Knoblauch P; de Bono JS
Br J Cancer; 2010 Jun; 103(1):12-7. PubMed ID: 20588278
[TBL] [Abstract][Full Text] [Related]
16. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Glasspool RM; Brown R; Gore ME; Rustin GJ; McNeish IA; Wilson RH; Pledge S; Paul J; Mackean M; Hall GD; Gabra H; Halford SE; Walker J; Appleton K; Ullah R; Kaye S;
Br J Cancer; 2014 Apr; 110(8):1923-9. PubMed ID: 24642620
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Coulter DW; Walko C; Patel J; Moats-Staats BM; McFadden A; Smith SV; Khan WA; Bridges AS; Deal AM; Oesterheld J; Davis IJ; Blatt J
Anticancer Drugs; 2013 Apr; 24(4):415-21. PubMed ID: 23328074
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; de Bono JS; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1117-1128. PubMed ID: 31667659
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
Von Hoff DD; Rasco DW; Heath EI; Munster PN; Schellens JHM; Isambert N; Le Tourneau C; O'Neil B; Mathijssen RHJ; Lopez-Martin JA; Edenfield WJ; Martin M; LoRusso PM; Bray GL; DiMartino J; Nguyen A; Liu K; Laille E; Bendell JC
Clin Cancer Res; 2018 Sep; 24(17):4072-4080. PubMed ID: 29764853
[No Abstract] [Full Text] [Related]
20. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Soriano AO; Yang H; Faderl S; Estrov Z; Giles F; Ravandi F; Cortes J; Wierda WG; Ouzounian S; Quezada A; Pierce S; Estey EH; Issa JP; Kantarjian HM; Garcia-Manero G
Blood; 2007 Oct; 110(7):2302-8. PubMed ID: 17596541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
